BTK and B-cell chronic lymphocytic leukemia: Some of these compounds act on several pathways aberrantly activated or expressed in CLL and include the inhibitor of Bruton’s tyrosine kinase (BTK) Ibrutinib and the inhibitor of B-cell lymphoma 2 protein (Bcl-2) Venetoclax [3].